CA2290695A1 - 5-naphthalen-1-yl-1,3-dioxane derivatives, preparation and therapeutic application - Google Patents

5-naphthalen-1-yl-1,3-dioxane derivatives, preparation and therapeutic application Download PDF

Info

Publication number
CA2290695A1
CA2290695A1 CA002290695A CA2290695A CA2290695A1 CA 2290695 A1 CA2290695 A1 CA 2290695A1 CA 002290695 A CA002290695 A CA 002290695A CA 2290695 A CA2290695 A CA 2290695A CA 2290695 A1 CA2290695 A1 CA 2290695A1
Authority
CA
Canada
Prior art keywords
group
general formula
mixture
naphthyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002290695A
Other languages
English (en)
French (fr)
Inventor
Patrick Lardenois
Jonathan Frost
Pascal George
Gihad Dargazanli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9706944A external-priority patent/FR2764287B1/fr
Priority claimed from FR9706947A external-priority patent/FR2764291B1/fr
Priority claimed from FR9706945A external-priority patent/FR2764288B1/fr
Priority claimed from FR9706946A external-priority patent/FR2764289B1/fr
Application filed by Individual filed Critical Individual
Publication of CA2290695A1 publication Critical patent/CA2290695A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002290695A 1997-06-05 1998-06-03 5-naphthalen-1-yl-1,3-dioxane derivatives, preparation and therapeutic application Abandoned CA2290695A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
FR97/06944 1997-06-05
FR97/06947 1997-06-05
FR9706944A FR2764287B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique
FR97/06946 1997-06-05
FR9706947A FR2764291B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique
FR9706945A FR2764288B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique
FR97/06945 1997-06-05
FR9706946A FR2764289B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique
PCT/FR1998/001113 WO1998055474A1 (fr) 1997-06-05 1998-06-03 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
CA2290695A1 true CA2290695A1 (en) 1998-12-10

Family

ID=27447000

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002290695A Abandoned CA2290695A1 (en) 1997-06-05 1998-06-03 5-naphthalen-1-yl-1,3-dioxane derivatives, preparation and therapeutic application

Country Status (18)

Country Link
EP (1) EP0986552A1 (es)
JP (1) JP2002502412A (es)
KR (1) KR20010013435A (es)
CN (1) CN1265658A (es)
AR (1) AR012908A1 (es)
AU (1) AU8025198A (es)
BG (1) BG103937A (es)
BR (1) BR9810742A (es)
CA (1) CA2290695A1 (es)
CO (1) CO4940480A1 (es)
EE (1) EE9900560A (es)
HU (1) HUP0002166A3 (es)
IL (1) IL133242A0 (es)
NO (1) NO995966L (es)
PL (1) PL337234A1 (es)
SK (1) SK166199A3 (es)
TR (1) TR199903022T2 (es)
WO (1) WO1998055474A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100792814B1 (ko) * 2000-07-21 2008-01-14 오르토-맥네일 파마슈티칼, 인코퍼레이티드 신경병증 통증 및 군발성 및 편두통성 두통-관련 통증의예방 또는 치료를 위해 사용하기 위한 카바메이트 화합물
FR2843964B1 (fr) 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0461958T3 (da) * 1990-06-15 1995-02-20 Synthelabo 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxanderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i terapien
FR2714055B1 (fr) * 1993-12-22 1996-01-19 Synthelabo Dérivés de 5-(arylalkyl)-1,3-dioxane substitués en position 2, leur préparation et leur utilisation en thérapeutique.
FR2742152B1 (fr) * 1995-12-06 1998-01-16 Synthelabo Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
BG103937A (en) 2000-07-31
NO995966D0 (no) 1999-12-03
HUP0002166A2 (hu) 2001-06-28
BR9810742A (pt) 2000-09-12
SK166199A3 (en) 2000-06-12
CO4940480A1 (es) 2000-07-24
IL133242A0 (en) 2001-03-19
AR012908A1 (es) 2000-11-22
EE9900560A (et) 2000-06-15
NO995966L (no) 2000-02-04
PL337234A1 (en) 2000-08-14
HUP0002166A3 (en) 2002-12-28
EP0986552A1 (fr) 2000-03-22
WO1998055474A1 (fr) 1998-12-10
JP2002502412A (ja) 2002-01-22
CN1265658A (zh) 2000-09-06
AU8025198A (en) 1998-12-21
TR199903022T2 (xx) 2000-04-21
KR20010013435A (ko) 2001-02-26

Similar Documents

Publication Publication Date Title
CN102203059B (zh) 取代的氨基茚满及其类似物以及其医药用途
KR100359393B1 (ko) 5-ht1a 길항제로서의 피페라진유도체 및 이의 제조방법
US5011928A (en) Analgesic and antiinflammatory derivatives of 1-acyl-4-arylalkylpiperazines
JP4861979B2 (ja) テトラヒドロイソキノリンスルホンアミド誘導体、その調製及び治療における同誘導体の使用
KR20070103454A (ko) 1,5-디아릴피롤 유도체, 그의 제조 방법, 및 치료제에서의그의 적용
IE831730L (en) Quinoline derivatives
JP5165578B2 (ja) イソキノリンおよびベンゾ［ｈ］イソキノリン誘導体、調製およびヒスタミンｈ３受容体のアンタゴニストとしてのこの治療上の使用
AU766655B2 (en) Amide compounds for the potentiation of cholinergic activity
JPH05186460A (ja) ２−（１−ピペリジル）エタノール誘導体、その製造方法およびその治療への適用
US5789425A (en) Imidazolidinone derivatives, their acid adducts and therapeutic drugs for senile dementia
US6242448B1 (en) Trisubstituted-oxazole derivatives as serotonin ligands
CA2172162C (en) Optically active imidazolidinone derivative and process for producing the same
JP2004507530A (ja) Ｎ−（３，５−ジクロロ−２−メトキシフェニル）−４−メトキシ−３−ピペラジン−１−イル−ベンゼンスルホンアミド
CZ281714B6 (cs) Piperidylmethylsubstituované deriváty chromanu
JPH08501287A (ja) アミド誘導体
CA2290695A1 (en) 5-naphthalen-1-yl-1,3-dioxane derivatives, preparation and therapeutic application
EP0315405A1 (en) 4-phenyl-4-(N-(2-fluorophenyl)amido) piperidine derivatives
WO2001009125A1 (fr) Nouveaux derives 8-carbonyl chromanes, leur preparation et leur utilisation en therapeutique
WO2001005767A1 (en) Organic compounds
AU705747B2 (en) 5-Naphthalen-1-yl-1,3-dioxane derivatives, their preparation and their therapeutic application
JP2002538152A (ja) セロトニン作動薬としての新規なジアゾール誘導体
MXPA99011203A (es) Derivados de 5-naftalen-1-il-1,3-dioxano, su preparacion y su aplicacion terapeutica
KR20070098882A (ko) 5-ｈｔ7 수용체 안타고니스트
JP2006514617A (ja) 疼痛または胃腸障害の治療のためのフェニル−ピペリジン−４−イリデン−メチル−ベンズアミド誘導体
CZ430699A3 (cs) Deriváty 5-naftalen-l-yl-l,3-dioxanu, způsob jejich přípravy a jejich terapeutické využití

Legal Events

Date Code Title Description
FZDE Discontinued